alisertib + cytarabine + idarubicin

Alisertib (MLN8237) is an investigational, orally bioavailable small molecule inhibitor of Aurora kinase A (AAK), a protein kinase essential for centrosome maturation and spindle assembly during mitosis. In the context of high-risk acute myeloid leukemia (AML), alisertib is being evaluated in combination with standard "7+3" induction chemotherapy, which typically consists of a seven-day continuous infusion of cytarabine and three days of an anthracycline such as idarubicin or daunorubicin. This combination therapy aims to overcome resistance in high-risk AML patients by combining the antimetabolite and DNA-intercalating effects of standard chemotherapy with the mitotic disruption caused by AAK inhibition. The regimen was notably studied in a Phase II trial led by Massachusetts General Hospital, demonstrating promising remission rates in previously untreated patients with high-risk AML.

Other names

alisertib + 7+3 induction chemotherapyalisertib + cytarabine + daunorubicin